Published: Jeffrey Cummings

Dr. Jeffrey Cummings (Brain Health) recently published an article, “The Role of Clinical Trials in Preclinical Alzheimer’s Disease Drug Development Programs," in the Journal of Prevention of Alzheimer’s Disease. The somewhat provocative findings note that despite the trend toward prevention trials becoming more likely (in part because trials in later stages of the disease have failed) they lack many of the essential aspects of successful clinical trials including a well defined target, enough decline in a placebo group, biomarkers to predict a clinical effect, and an interested market if the therapeutic agent works. Cummings concludes, "trials in patients with symptoms have a better chance of success in drug development trials than prevention trials." 

People in the News

portrait of Matthew Montalto, Admissions Analyst, Graduate College. 
People | August 10, 2020
It may not be the theater Matthew Montalto once dreamed of working in, but the admissions analyst loves his job at the UNLV Graduate College.
Nicole Santero at home, surrounded by BTS memorabilia, including a poster.
People | August 3, 2020
Nicole Santero balances her job communicating about the School of Public Health with her doctoral research on the BTS phenomenon.
Portrait of Steven Palazzo, the UNLV Schoool of Nursing's new associate dean for academic affairs
People | July 27, 2020
The nurse/educator sees the remote learning necessitated by the pandemic as an opportunity for growth.